ATF Medical Launches Pressure Injury Prevention and Intervention Program

ATF Medical has introduced its Pressure Injury Prevention and Intervention (PIPI) program to make sure that everyone involved in a workers’ compensation case has the information needed to prevent or properly treat pressure injuries, also known as wounds.

“There is a large body of information from credible nursing, rehabilitation, and equipment manufacturers about pressure injuries, but it is not all in one place, and not customized to the individual and circulated to all the providers who need it,” said ATF Medical’s Director of Rehab Technology Edwina Murphy, OTR, ATP.

The PIPI program reviews clients’ claims to identify injured workers at risk of developing pressure injuries and recommends ways to avoid them. When wounds already exist, ATF Medical’s professionals evaluate the injured worker’s condition and environment and uses pressure mapping systems for chairs and mattresses to detect pressure points.

“Pressure mapping helps identify a seat or mattress issue, often something that can be easily and inexpensively adjusted,” Murphy explained. “It’s an eye-opening educational tool. When injured people can see how relieving pressure affects the colors on the map, they’re more apt to comply with relief techniques and other self-management guidance.”

ATF Medical designs a customized pressure management program for the injured worker, synthesizing relevant treatment protocols, durable medical equipment data, and educational materials, and shares it with the injured worker, providers, and the claim representative. The report recommends solutions, such as pressure relief schedules to increase circulation or obtaining power-assisted tilt for a person who cannot move him or herself.

“Our program is designed to avoid and reduce costs through proper communication, coordination and accountability,” Murphy said. For more information on the ATF Medical Pressure Injury and Prevention Program, please contact Murphy at emurphy@atfmedical.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”